`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_______________________
`
`PAR PHARMACEUTICAL, INC.,
`Petitioner
`
`v.
`
`SUMITOMO DAINIPPON PHARMA CO., LTD.,
`Patent Owner
`_______________________
`
`Case IPR2017-01292
`U.S. Patent No. 9,555,027
`_______________________
`
`JOINT MOTION TO TERMINATE PROCEEDING
`PURSUANT TO 35 U.S.C. § 317 AND 37 C.F.R. § 42.74
`
`
`
`IPR2017-01292
`U.S. Patent No. 9,555,027
`Pursuant to 35 U.S.C. § 317, 37 C.F.R. § 42.74, and the Board’s e-mail of
`
`July 27, 2017, Petitioner Par Pharmaceutical, Inc. (“Par”) and Patent Owner
`
`Sumitomo Dainippon Pharma Co., Ltd. (“Sumitomo”) jointly move to terminate
`
`the present inter partes review proceeding in light of the parties’ resolution of their
`
`dispute relating to U.S. Patent No. 9,555,027 (“the ’027 Patent”).
`
`As required by 35 U.S.C. § 317(b), the parties are concurrently filing a true
`
`copy of the parties’ agreement (executed on May 31, 2017) as Exhibit 2002.1 The
`
`parties are also concurrently filing a motion to seal pursuant to 35 U.S.C. § 327(b)
`
`and 37 C.F.R. § 42.74(c), requesting that the agreement (Ex. 2002) be treated as
`
`confidential business information and kept separate from the files of the involved
`
`patent.
`
`Because the agreement resolves the current dispute between the parties, the
`
`parties jointly request that this proceeding be terminated under 35 U.S.C. § 317(a)
`
`and 37 C.F.R. § 42.74. See Fandango, LLC et al. v. Ameranth, Inc., CBM2014-
`
`00013, Paper 22 at 5-6 (March 24, 2014). There are no additional collateral
`
`agreements or understandings made in connection with, or in contemplation of,
`
`termination of the inter partes review.
`
`
`1 This agreement was filed via E2E for “Parties and Board Only” to preserve
`
`confidentiality.
`
`1
`
`
`
`IPR2017-01292
`U.S. Patent No. 9,555,027
`“An inter partes review instituted under this chapter shall be terminated with
`
`respect to any petitioner upon the joint request of the petitioner and the patent
`
`owner, unless the Office has decided the merits of the proceeding before the
`
`request for termination is filed.” 35 U.S.C. § 317(a); see also Office Patent Trial
`
`Practice Guide, 77 Fed. Reg. 48, 756, 46,768 (Aug. 14, 2012) (“The Board expects
`
`that a proceeding will terminate after the filing of a settlement agreement, unless
`
`the Board has already decided the merits of the proceeding.”).
`
`Because trial has not been instituted and the Board has not decided the
`
`merits of the proceeding, terminating this proceeding is appropriate, conserving the
`
`resources of the Board and the parties. In fact, Patent Owner has not yet filed a
`
`preliminary response, and the Board has not decided whether to institute. Further,
`
`strong public policy considerations favor agreement between the parties to an inter
`
`partes review proceeding. See Bergh v. Dept. of Transp., 794 F.2d 1575, 1577
`
`(Fed. Cir. 1986) (“The law favors settlement of cases.”); see also Office Trial
`
`Practice Guide, 77 Fed. Reg. at 48,768. No public interest or other factors weigh
`
`against termination of this proceeding.
`
`In its e-mail of July 27, 2017, the Board also indicated that this motion must
`
`“identify all parties in any related district court litigation involving the patent(s) in
`
`dispute and discuss the current status of each such related litigation with respect to
`
`each party to the litigation” and “identify the case numbers of any pending, related
`
`2
`
`
`
`IPR2017-01292
`U.S. Patent No. 9,555,027
`inter partes review proceedings.” There are no such related district court litigations
`
`or inter partes review proceedings.
`
`For the foregoing reasons, the parties jointly and respectfully request that the
`
`instant proceeding be terminated.
`
`
`
`
`
`3
`
`
`
`IPR2017-01292
`U.S. Patent No. 9,555,027
`Date: August 1, 2017
`
`
`
`
` By: /Daniel G. Brown/
`
`Daniel G. Brown (Reg. No. 54,005)
`Latham & Watkins LLP
`885 Third Avenue
`New York, NY 10022-4834
`Tel: (212) 906-1200
`Fax: (212) 751-4864
`daniel.brown@lw.com
`
`Lead Counsel for Petitioner Par
`Pharmaceutical, Inc.
`
`
`By: /Preston K. Ratliff II/
`Preston K. Ratliff II (Reg. No. 43,034)
`Paul Hastings LLP
`200 Park Avenue
`New York, NY 10166
`Telephone: (212) 318-6055
`Facsimile: (212) 230-7742
`PH-Par-SunovionIPR@paulhastings.com
`
`Lead Counsel for Patent Owner
`Sumitomo Dainippon Pharma Co., Ltd.
`
`4
`
`
`
`
`
`IPR2017-01292
`U.S. Patent No. 9,555,027
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 1st day of August,
`
`2017, a copy of Joint Motion to Terminate Proceeding was served by electronic
`
`mail on Petitioner’s lead and backup counsel at the following email addresses:
`
`daniel.brown@lw.com
`jonathan.strang@lw.com
`
`
`
`
`
`
`
`
`
`By: /Preston K. Ratliff II/
`Preston K. Ratliff II (Reg. No. 43,034)
`Paul Hastings LLP
`200 Park Avenue
`New York, NY 10166
`Telephone: (212) 318-6055
`Facsimile: (212) 230-7742
`PH-Par-SunovionIPR@paulhastings.com
`
`Lead Counsel for Patent Owner
`Sumitomo Dainippon Pharma Co., Ltd.
`
`